WHO Funds Vaxxas Research for Global Nanopatch Polio Vaccine

Vaxxas has announced the initiation of a research project to evaluate Vaxxas' proprietary Nanopatch platform for delivery of polio vaccine. The Nanopatch induces robust immune system activation by targeting vaccine to the abundant immunological cells immediately below the surface of the skin. 

The World Health Organization (WHO) will provide funding to Vaxxas to support its polio vaccination research, specifically for preclinical studies and good manufacturing practices (GMP). Following the successful completion of this research, and all subsequent necessary clinical development and regulatory approvals, Vaxxas would have the opportunity to supply Nanopatches to help secure a lasting polio-free world.

"The Nanopatch doesn’t need to be kept refrigerated to maintain its efficacy — a tremendously important factor for the transportation and application of polio vaccine in the remote regions of the world where eradication efforts are most challenging," said David L. Hoey, CEO of Vaxxas. "The research we are undertaking with WHO’s support aims to provide better vaccine solutions to reach all children anywhere with this life-saving health intervention."